Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.

US Press Releases


NSD | NYE | AMX | OTC:BB | 

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

EOI
EOS
ETB
ETJ
ETO
ETV
ETW
ETY
EVG
EXG
Eaton Vance Closed-End Funds Release Estimated Sources of Distributions May 29, 2015 02:13 PM

MRK New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status May 29, 2015 02:06 PM

MRK First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck's KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine May 29, 2015 02:05 PM

HRZ
MATX
Matson Completes Alaska Acquisition For $469 Million May 29, 2015 02:04 PM

HRZ
MATX
Matson Completes Alaska Acquisition For $469 Million May 29, 2015 02:04 PM

BMY Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb's PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma May 29, 2015 02:02 PM

BMY Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial May 29, 2015 02:02 PM

CCE Coca-Cola Enterprises, Inc. to Webcast Presentation to Deutsche Bank Global Consumer Conference May 29, 2015 02:01 PM

DCI Donaldson Increases Quarterly Dividend and Authorizes New Share Repurchase Program May 29, 2015 02:00 PM

BRCM Broadcom Corporation Stockholders Encouraged to Contact Securities Law Firm about Takeover May 29, 2015 02:00 PM

RALY Rally Software Development Corp. Stockholders Encouraged to Contact Securities Law Firm about Takeover May 29, 2015 02:00 PM